{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NKTR-102",
    "query": {
      "intervention": "NKTR-102"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NKTR-102&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T15:26:04.235Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00806156",
      "title": "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102 q14d",
          "type": "DRUG"
        },
        {
          "name": "NKTR-102 q21d",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 178,
      "start_date": "2008-10",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 11,
      "location_summary": "Highland, California • Los Angeles, California • Newport Beach, California + 8 more",
      "locations": [
        {
          "city": "Highland",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00806156"
    },
    {
      "nct_id": "NCT01663012",
      "title": "Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Astrocytomas",
        "Anaplastic Oligodendrogliomas",
        "Glioblastomas (GBM)"
      ],
      "interventions": [
        {
          "name": "Etirinotecan pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lawrence Recht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2012-07",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-02-24",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01663012"
    },
    {
      "nct_id": "NCT01976143",
      "title": "A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2014-02",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-12-22",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Francisco, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01976143"
    },
    {
      "nct_id": "NCT02312622",
      "title": "Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer (NSCLC)",
        "Recurrent Non-small Cell Lung Cancer (NSCLC)",
        "Extensive-stage Small Cell Lung Cancer (SCLC)",
        "Recurrent Small Cell Lung Cancer (SCLC)",
        "Tumors Metastatic to Brain",
        "Metastatic Breast Cancer (mBC)"
      ],
      "interventions": [
        {
          "name": "Pegylated Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joel Neal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2015-08",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312622"
    },
    {
      "nct_id": "NCT01492101",
      "title": "The BEACON Study (Breast Cancer Outcomes With NKTR-102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Recurrent Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        },
        {
          "name": "Treatment of Physician's Choice (TPC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 852,
      "start_date": "2011-12",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 88,
      "location_summary": "Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492101"
    },
    {
      "nct_id": "NCT00802945",
      "title": "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2008-10",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2018-07-09",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Rancho Mirage, California • Stockton, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802945"
    },
    {
      "nct_id": "NCT01773109",
      "title": "Etirinotecan Pegol (NKTR-102) in NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer",
        "Recurrent Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Etirinotecan pegol (NKTR-102)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-01",
      "completion_date": "2017-03-15",
      "has_results": true,
      "last_update_posted_date": "2020-04-03",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773109"
    },
    {
      "nct_id": "NCT01991678",
      "title": "A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "145 mg/m2 NKTR 102",
          "type": "DRUG"
        },
        {
          "name": "120 mg/m2 NKTR 102",
          "type": "DRUG"
        },
        {
          "name": "50 mg/m2 NKTR 102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-11",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Francisco, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01991678"
    },
    {
      "nct_id": "NCT02915744",
      "title": "A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastasis",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2016-11",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Orange, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915744"
    },
    {
      "nct_id": "NCT00856375",
      "title": "NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        },
        {
          "name": "irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2008-12",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-09-05T15:26:04.235Z",
      "location_count": 9,
      "location_summary": "Peoria, Arizona • Burbank, California • Los Angeles, California + 6 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Centralia",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856375"
    }
  ]
}